Latest News and Press Releases

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company...

Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Axial Spondyloarthritis (axSpA) Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global axial...

New York, United States , April 21, 2023 (GLOBE NEWSWIRE) -- The Global Axial Spondyloarthritis (axSpA) Market Size is to grow from USD 5.2 billion in 2022 to USD 10.1 billion by 2032, at a Compound...

NEWARK, Del, March 31, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Axial Spondyloarthritis management market is expected to grow at a value of 5.1% CAGR, according to...

Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight The report offers...

Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Axial Spondyloarthritis (axSpA)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the...